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introDuction 
Colorectal cancer (CRC) is one of the commonest cancers in the 
Maltese population but can be treated successfully if detected 
early. The major components of early detection are education 
and screening.1  
People with a family history of CRC but with no genetic 
disorder putting them at high risk of CRC are considered to be 
at moderate risk of developing CRC. These are further divided 
into high/moderate and low/moderate-risk subcategories. The 
preferred surveillance mode for patients with a moderate risk of 
developing CRC is total colonoscopy.2
The aims of this audit are to:
•	 Evaluate	the	colonoscopy	screening	pattern	for	individuals	
with a family history indicating moderate risk for CRC in a 
surgical firm at Mater Dei Hospital.
•	 Compare	this	pattern	with	that	recommended	by	the	NICE	
guidelines.
MethoDology 
setting anD Data collection
This retrospective study was conducted at Mater Dei 
Hospital between April - June 2015 within a surgical firm that 
records its endoscopic services on iSOFT, which is a secure 
database utilised at Mater Dei Hospital.  
A total of 90 patients having one or more first degree 
relatives (FDRs) affected by colorectal cancer who had 
undergone at least one colonoscopy between November 2007 - 
January 2015 were identified. Their respective age, indication for 
colonoscopy, date of procedure and findings were retrieved from 
the database.
These patients were then phoned and asked about:
1. The number of relatives and degree of relation of relatives 
affected by CRC;
2. Age of relative/s at time of diagnosis with CRC;
3. Presence of gastrointestinal - related symptoms prior to 
colonoscopy;
4. Number of colonoscopies and the respective dates at which 
they were performed; 
5. Any other investigative procedures done for the same 
condition.
A summary of the NICE guidelines for colorectal cancer 
screening and surveillance is shown in Table 1. Compliance for 
each parameter was awarded a 25% score. Compliance to all 
categories was given a 100% compliance. The average percentage 
compliance was then calculated for all patients within each risk 
category. Any discordance between the guidelines and actual 
practice was recorded.
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abstract 
Colorectal cancer is one of the commonest forms of cancer 
in the Maltese population. It can be treated successfully 
if detected early. Education and screening are the major 
components of early detection. The aim of this study was 
to determine the pattern of colonoscopy screening in 
patients at moderate risk of developing colorectal cancer 
in a surgical firm at Mater Dei Hospital. 90 patients that 
fit into the moderate-risk category were identified from 
the firm’s endoscopy database. The pattern of screening 
was then compared to the NICE guidelines. It was found 
that colonoscopy screening was more aggressive than 
recommended by the NICE guidelines.
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stanDarD useD
The guidelines used were the NICE Guidelines for 
colorectal cancer screening and surveillance in moderate-risk 
family groups.2 These were updated by The British Society of 
Gastroenterology (BSG) and the Association of Coloproctology 
for Great Britain and Ireland (ACPGBI) in 2002.
Data analysis
All data were processed using Microsoft Excel 2013 and 
analysed by comparing the number of colonoscopies performed 
between November 2007 - January 2015 for every patient, with 
the screening procedure and respective interval recommended 
by the NICE Guidelines.2 The parameters required to assess 
compliance with guidelines included:
1. The number of first degree relatives affected;
2. Age of diagnosis of such relative/s;
3. Age of patient at which colonoscopy was first undergone;
4. Number of colonoscopies within a 5-year interval.
Any discordance between the guidelines and actual practice 
was recorded.
ethical aPProVal anD consent
The study was approved by the Audit and Data Protection 
Act Committee and the Mater Dei Hospital data protection Unit. 
Consent was obtained from the Consultant Surgeon of the Firm. 
results
As shown in Figure 1 the greatest number of patients fell in 
the ‘other Family history of CRC category’, (35 from 90 patients; 
39%). Average compliance to the NICE guidelines was greatest 
in the low/moderate-risk category (75%) while the lowest 
compliance was observed in the other family history of CRC 
category (25%), as shown in Figure 2.
There was 100% compliance in all categories to the NICE 
recommendations pertaining to the screening process of patients 
with FDR having a history of CRC (Table 2). Compliance 
to mean age at which relatives were diagnosed with CRC 
was 100% in the high/moderate-risk and low/moderate-risk 
categories. All the patients screened had one or more first degree 
relatives with history of colorectal cancer, so compliance to this 
parameter was fulfilled in all categories. The mean age at which 
the affected relatives were diagnosed with colorectal cancer 
was also complied with in the low/moderate-risk category 
and high/moderate-risk category.  However, compliance to 
the recommended frequency of screening and age at which to 
start screening was low in all categories. Overall percentage 
compliance to the NICE guidelines across all categories was 11% 
(Figure 3).
Discussion 
faMily history categories anD recoMMenDations 
A positive family history of CRC confers an increased risk 
for the development of CRC.3 
The study considered the moderate-risk category which is 
further divided into high/moderate-risk and low/moderate-risk. 
The remaining patients fell into the ‘other family history of CRC’ 
category.
i. The high/moderate-risk category1 includes:
1. Patients with 3 or more affected relatives in a first degree 
kinship with each other (none <50 years old as otherwise 
they would fulfil high risk criteria).
2. Two affected relatives with a mean age <60 years in a first 
degree kinship.
Recommendation
In  this  category  patients  merit  low  intensity  surveillance  
comprising 5-yearly colonoscopy commencing at age 50 
and continuing till 75 years of age. Polyps must be snared 
and  histologically characterised. If adenomas are  present,  
surveillance should be instigated as per adenoma surveillance 
guidelines.2
ii. The low/moderate-risk category1 includes:
1. Patients with only one affected relative <50 years old.
2. Patients with only two affected first degree relatives aged 60 
years or older.
Recommendation
Once only colonoscopy at 55 years of age.  Polyps must 
be snared and histologically characterised.  If adenomas  are  
present  surveillance  should  be  instigated  as per adenoma 
surveillance guidelines.2
Figure 1. Number and percentage of patients in each moderate risk category 	
	
Figure 2. The average percentage of compliance in each moderate risk category 	
	
 
 
25
28%
30
33%
35
39%
High Moderate Risk Low Moderate Risk Other Family history of Colorectal cancer
60%
75%
25%
0%
10%
20%
30%
40%
50%
60%
70%
80%
High Moderate  
Risk
Low Moderate  
Risk 
Other FH of 
CRC
n: 22.5
n: 15
n: 8.75
Figure 1. Number and percentage of patients in each moderate risk category 
20 Volume 15, 2016  Issue 01
Figure 2. The average percentage of compliance in each moderate risk category 
Figure 1. Number and percentage of patients in each moderate risk category 	
	
Figure 2. The average percentage of compliance in each moderate risk category 	
	
 
 
25
28%
30
33%
35
39%
High Moderate Risk Low Moderate Risk Other Family history of Colorectal cancer
60%
75%
25%
0%
10%
20%
30%
40%
50%
60%
70%
80%
High Moderate  
Risk
Low Moderate  
Risk 
Other FH of 
CRC
n: 22.5
n: 15
n: 8.75
Figure 3. Overall compliance to the NICE guidelines 
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Overall compliance 
to the NICE guidelines
 iii. All other family history of CRC1
Recommendation
No need for screening.
coMPliance with screening recoMMenDations
Most patients screened had a family history of CRC but 
did not fit the criteria for low or high moderate-risk. The 
highest average percentage compliance (75%, n=22.5) was 
found in the low/moderate-risk category (Figure 2).
a. Compliance in the High/Moderate-Risk Category
In the high/moderate-risk category, full compliance 
was observed with regards to the NICE criteria relating 
to the screening of patients that had first degree relatives 
with a history of CRC as well as the mean age at which the 
relatives were diagnosed. Compliance was not observed with 
regard to the number of recommended colonoscopies as 
there was a tendency to screen every 2 years rather than the 
recommended 5-year interval. When it came to the age of 
first colonoscopy, delayed and early screening initiation were 
equally observed.  Unawareness of the guidelines, practice of 
defensive medicine and pressure from patients could all be 
reasons for non-compliance.  
b. Compliance in the Low/Moderate-Risk Category
Most patients in this category had more colonoscopies 
than recommended by the guidelines.  Reasons for this may 
be similar as for the high/moderate-risk category, that is 
inadequate history taking leading to improper categoris ion 
of patients, unawareness of the guidelines and the practice 
of defensive medicine by the clinician. Pressure from the 
patient and/or relatives, mainly due to anxiety and insecurity 
may also have contributed to this.
With regards to the age at which screening was initiated, 
non-compliance was due to delayed screening initiation 
rather than early screening initiation. Delayed screening 
initiation may occur if the patient is not under the care of a 
primary health care provider at the time at which screening 
is supposed to start. Primary health care providers have 
an important role to play in advising patients when they 
should have their first screening colonoscopy as advised by 
guidelines and according to which risk category they are 
in. Another reason for delayed screening initiation is that 
the patient may be older than the recommended age for 
screening initiation by the time CRC is discovered in his/
her relatives. Health care providers’ lack of knowledge of 
the screening guidelines may also contribute to delayed 
screening initiation.
c. Compliance in Patients with ‘Other Family History of CRC’
According to the NICE guidelines, screening is not 
recommended for those patients with a family history of 
CRC that did not fall into either of the above categories. 
Hence, these patients should not have had a colonoscopy. The 
study showed that screening was mainly conducted on the 
basis of whether the patient had a first degree relative with a 
history of CRC or not. The main reasons for non-compliance 
in this category are the same as the ones mentioned for the 
previous categories, that is, limited sampling units, pressure 
to perform screening by the patient or relatives, the practice 
of defensive medicine and the possible belief of some 
clinicians that the guidelines for screening are not stringent 
enough and that following them may lead to missed cases of 
CRC.
As for any other guidelines, dissemination, accessibility, 
clarity and regular updating of guidelines is essential to 
ensure clinician awareness and to improve compliance.
outcoMes of the screening colonoscoPies PerforMeD
Across all categories, in 50% (n=45) of the colonoscopies 
carried out, no abnormality was detected (Figure 4). 
Of the patients that did not fall into low or high/
moderate-risk categories, only 14% had polyps on 
colonoscopy.  This supports the recommendation of the 
guidelines that screening is not to be performed in this 
category of patients.
It is suggested that left-sided hyperplastic colonic polyps 
(generally within the reach of a screening sigmoidoscopy) 
serve as a marker for neoplastic polyps.4
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German-maltese medIcal socIety Update
Also present at the signing of the memorandum were  
Prof. Dr Rudolf Hesterberg Medical Director, Mr Michael Gribner CEO  
and Mr Christian Collard Human Resources Manager at RCH 
sIGnInG of moU Between the mInIstry  of enerGy 
& health and red cross hospItal
a delegation from Malta visited the Red Cross Hospital (RCH) in Kassel, Germany on the 14th of December to review an ongoing co-operation and to discuss areas in 
which further co-operation can be carried out. Accompanying 
his Excellency Mr Albert Friggieri, who in his capacity as 
Maltese ambassador in Germany had already visited the RCH, 
there were Dr Chris Fearne, Parliamentary Secretary of the 
Maltese Ministry of Energy & Health (MEH), Dr Ray Galea, 
Head of Specialist Medical Education at the University of 
Malta, and Dr Antoinette Calleja Director of International 
Relations at the MEH. In addition to the successful Clinical 
Clerkship Project for Maltese medical students which started 
in 2013, further expansion in other fields are planned, 
including specialist exchange in the sphere of medical 
technical services. Within the framework of this visit an 
agreement was signed by the MEH of Malta and the RCH 
with a view to reach these objectives. 
liMitations 
The main limitations were:  
a. The cohort of patients all belonged to the same surgical 
firm;
b. The small sample size;
c. The patients may have forgotten certain details by the time 
of interview;
d. Time constraints limited the assessment of the overall 
survival in all referrals according to their risk category.
conclusion anD recoMMenDations 
The tendency is to screen more aggressively than 
recommended by the NICE guidelines, possibly due to 
inaccurate history taking and improper patient categorization, 
unawareness of the guidelines, the practice of defensive 
medicine and pressure from anxious patients and relatives. 
To improve compliance, it is recommended that the NICE 
guidelines should be easily accessible, clear, well-disseminated 
and regularly updated. There should be more clinician awareness 
of the unnecessary stress, inconvenience and discomfort 
that excessively aggressive screening can cause to patients. In 
patients that fell into the ‘other family history of CRC’ category, 
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polyps were only found in 14%, supporting the guidelines’ 
recommendation that screening is not necessary in these 
patients. 
the tenDency is to screen More aggressiVely 
than recoMMenDeD by the nice guiDelines
23Volume 15, 2016  Issue 01
